Keep It Simple Stupid: Making Intranasal Biologic Drugs for Population Scale Access
Time: 12:00 pm
day: Day 1
Details:
- GMP scalability and COGS once made intranasal biologics impossible
- New technology makes this feasible today, unlocking key advantages in development costs, commercial viability, and equitable access
- How to think about optimally balancing the tradeoffs between safety, purity, and developability
